Mitomycin
Jelmyto, Mitomycin, Mitosol (mitomycin) is a small molecule pharmaceutical. Mitomycin was first approved as Mutamycin on 1982-01-01. It is used to treat adenocarcinoma, colorectal neoplasms, pancreatic neoplasms, stomach neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Jelmyto, Mitomycin, Mitosol (discontinued: Mitomycin, Mitozytrex, Mutamycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitomycin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MITOSOL | Mobius Therapeutics | N-022572 RX | 2012-02-07 | 1 products, RLD, RS |
| JELMYTO | UroGen Pharma | N-211728 RX | 2020-04-15 | 1 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
| pancreatic neoplasms | EFO_0003860 | D010190 | C25 |
| stomach neoplasms | EFO_0003897 | D013274 | C16 |
| urinary bladder neoplasms | — | D001749 | C67 |
| adenocarcinoma | — | D000230 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MITOMYCIN, JELMYTO, UROGEN PHARMA | |||
| 2027-04-15 | ODE-289 | ||
Clinical
Clinical Trials
374 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | — | — | — | 1 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mitomycin |
| INN | mitomycin |
| Description | Mitomycin C is a mitomycin. It has a role as an antineoplastic agent and an alkylating agent. It is a conjugate acid of a mitomycin C(1-). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 50-07-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL105 |
| ChEBI ID | 27504 |
| PubChem CID | 5746 |
| DrugBank | DB00305 |
| UNII ID | 50SG953SK6 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Jelmyto – UroGen Pharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,435 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mitomycin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,194 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use